Abcl stock forecast 2025 aligns with biotech sector recovery

ABCL stock forecast 2025 aligns with biotech sector recovery cycles projected by market strategists. If sector sentiment improves broadly, ABCL could outperform the average biotech peer index by 5–8%. One of the key areas of focus for AbCellera Biologics Inc. (NASDAQ:ABCL) is its T-cell engager (TCE) platform, which has significant potential in the treatment of cancer. The TCE platform is a technology that enables the creation of bispecific antibodies that can selectively activate T-cells to attack cancer cells. The company believes that its TCE platform has the potential to be a game-changer in the treatment of cancer, and is investing heavily in its development. To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. ABCL stock forecast 2025 data models indicate possible 20% year-over-year revenue growth if early-stage candidates move into Phase 2 trials. Biotech sector liquidity cycles suggest that sustained investor focus could drive valuation multiples above 8× EV/revenue.